Cost-effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial

Journal of Medical Economics

Volumn 6, Issue 55-68, 2003, Pages 55-68

  Annemans, L ^a,b   Lamotte, M ^a   Levy, E ^c   Lenne, X ^d  

^a HEDM   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITÉ PARIS DAUPHINE   (France)

^d UNIVERSITÉ CATHOLIQUE DE LILLE   (France)

Author keywords

Atherosclerosis; Clopidogrel; Cost effectiveness; Economic

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HEALTH ECONOMICS; HEART MUSCLE ISCHEMIA; HUMAN; LIFE EXPECTANCY; NEUTROPENIA; PEPTIC ULCER; PROBABILITY; RASH; SECONDARY PREVENTION; SIDE EFFECT; STATISTICAL MODEL; SURVIVAL; THROMBOSIS; VASCULAR DISEASE;

EID: 0042236712     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/200306055068     Document Type: Article

References (33)

1. Website of the Belgian National Institute of statistics (http://www.statbel.fgov.be/) 2002.
2. De Henauw S, De Bacquer D, de Smet P et al. Trends in coronary heart disease in two Belgian areas: results from the MONICA Ghent-Charleroi study. Journal of Epidemiology and Community Health 1999; 53: 89-99.
3. Website of the Belgian Scientific Institute of Public Health (http://www.iph.fgov.be/epidemio/morbidat/NL/) 2002
4. Verhaeghe R. Epidémiologie et pronstic de l'artériopathie oblitérante des membres inférieurs. Drugs 1998; 56 (Suppl. 3): 1-10.
5. Dormandy J. Natural history of intermittent claudication. Hospital Update 1991; 17:314-320.
6. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
7. Hlatky MA. Role of economic models in randomised clinical trials. American Heart Journal 1999; 137 (Suppl.): S41-S46.
8. Baltussen R, Leidl R, Ament A. Real world designs in economic evaluation. Bridging the gap between clinical research and policy making. Pharmacoeconomics 1999; 16: 449-458.
9. Belgian Society for Pharmacoepidemiology. Standard report format for economic evaluation of pharmaceuticals. Belgium
10. Saskatchewan Health. Saskatchewan's health information resources. Research Services. Strategic programs branch, Canada 1995.
11. Institut Nationale d'Assurance Maladie-Invalidité. Noménclature 2002.
12. Répertoire Commenté des médicaments de Belgique: http://www.bcfi.be/
13. Doubilet P, Begg CB, Weinstein MC, Braun P et al. Probabilistic sensitivity analysis using Monte Carlo simulation. Medical Decision Making 1985; 5: 155-177.
14. Frend JE, Walpole RE. Mathematical Statistics. Prentice-Hall International, 1987.
15. Clark DE. Computational methods for probabilistic decision trees. Computers and Biomedical Research 1997; 30: 19-33.
16. Law AM, Kelton WD. Simulation Modelling and Analysis. New York, NY: McGraw-Hill, 1991.
17. Postma MJ, Heijnen ML, Beutels P et al. Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis. Ned Tijdschr Geneeskd 2002; 146: 855-889.
18. Young M, Plosker GL. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer. Pharmacoeconomics 2001; 19: 1227-1259.
19. Berthelot JM, Will BP, Evans WK et al. Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer. Journal of the National Cancer Institute 2000; 92: 1321-1329.
20. Gorelick PB, Born GVR, D'Agostino RB et al. Therapeutic benefit. Aspirin revisited in light of the introduction of clopidogrel. Stroke 1999; 30: 1716-1721.
21. Marissal JP, Selke B, Lebrun T. Economic assessment of the secondary prevention of ischaemic events with lysine acetylsalicylate. Pharmacoeconomics 2000; 18: 185-200.
22. Oster G, Huse DM, Lacy MJ et al. Cost-effectiveness of ticlodipine in preventing stroke in high-risk patients. Stroke 1994; 25: 1149-1156.
23. Chambers M, Hutton J, Gladman J. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Pharmacoeconomics 1999; 16: 577-593.
24. Sarasin FP, Gaspoz J-M, Bounameaux H. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischaemic attack. Archives of Internal Medicine 2000; 160: 2773-2778.
25. Hadelmann R, Szucs T.D, Luscher T. Rentabilité du clopidogrel dans la prévention secondaire cardio-vasculaire: une analyse coût-efficacité sur la base de l'étude CAPRIE. Medical Hygiene 2001; 59: 1749-1754.
26. Gaspoz JM, Coxson PG, Goldman PA et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. New England Journal of Medicine 2002; 346: 1800-1806.
27. de Lemos JA, McGuire DK. Aspirin, clopidogrel, or both for secondary prevention of coronary disease. New England Journal of Medicine 2003; 348: 561.
28. Muls E, Van Ganse E, Closon MC. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model. Atherosclerosis 1998; 137 (Suppl.): S111-S116.
29. Franzosi MG, Brunetti M, Marchioli R et al. GISSI-Prevenzione Investigators. Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial. Pharmacoeconomics 2001; 19: 411-420
30. Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal 2003; 24: 28.
31. Brown RE, Henderson RA, Koster D et al. Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using IntegrilinTherapy. European Heart Journal 2002; 23: 50-58.
32. Caro JJ, Migliaccio-Walle K. Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events. American Journal of Medicine 1999; 107: 568-572.
33. Salomaa V, Rosamond W, Mahonen M. Decreasing mortality from acute myocardial infarction: effect of incidence and prognosis. Journal of Cardiovascular Risk 1999; 6: 69-75.